SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma

Table 1 Registries on severe asthma currently available in USA and Europe

Registry (reference)	Country	No. of centers	Study population	Outcomes
TENOR [8, 9]	USA	283	4.756	Natural history of SA
BSAR [10]	Belgium	9	350	Definition of clinical phenotypes in SA
Spanish Multi-Centers Registry [11]	Spain	30	266	Omalizumab efficacy
Spanish Multi-Centers Registry [12]	Spain	30	295	Omalizumab efficacy
NEONET [13]	Italy	9	112	Omalizumab efficacy and safety
ARRISA [14]	UK	29 Primary care practices	911	Impact of the network on exacerbation
BTS Severe Refractory Asthma Registry [15]	UK	4	382	Phenotype characterization, standardized assessment
BTS Severe Refractory Asthma Registry [16]	UK	4	349	Three years follow up
BTS Severe Refractory Asthma Registry [17]	UK	4	349	Phenotype stability over time
BTS Severe Refractory Asthma Registry [18]	UK	7	516	Economic analysis of SA
BTS Severe Refractory Asthma Registry [19]	UK	7	808	Comorbidity due to the use of systemic steroid

TENOR The epidemiology and natural history of asthma:outcomes and treatment regimens, BSAR Belgian Severe Asthma Registry, NEONET Italian North-East Omalizumab Network, ARRISA at risk register in severe asthma, BTS British Thoracic Society

ISSN: 1476-7961